Similar to rapamycin, everolimus induces AKT activation while inhibiting mTOR signaling in human cancer cells, including NSCLC cells, as well as in tumor biopsies (Wang et al., 2008; O'Reilly et al., 2006). Here, AKT1 is linked to neoplasm.